Cardiff Oncology Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
CRDF$0.80+5.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
| PreferredStockShares · PreferredStockAmount · CommonStockShares · CommonStockAmount · Additional Paid-InCapital · AccumulatedOtherComprehensiveGain (Loss) · AccumulatedDeficit · TotalStockholders’Equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Balance, December 31, 2022 | 61 | $— | 44,677 | $4 | $404,834 | $(395) | $(298,100) | $106,343 | |
| Stock-based compensation | — | — | — | — | 4,509 | — | — | 4,509 | |
| Other comprehensive gain | — | — | — | — | — | 328 | — | 328 | |
| Net loss | — | — | — | — | — | — | (41,441) | (41,441) | |
| Balance, December 31, 2023 | 61 | — | 44,677 | 4 | 409,343 | (67) | (339,541) | 69,739 | |
| Modified-retrospective adoption of ASU 2020-06(1) | — | — | — | — | (793) | — | 793 | — | |
| Issuance of common stock, net of expenses(2) | — | — | 21,708 | 3 | 53,404 | — | — | 53,407 | |
| Stock-based compensation | — | — | — | — | 4,760 | — | — | 4,760 | |
| Issuance of common stock upon exercise of stock options | — | — | 139 | — | 373 | — | — | 373 | |
| Other comprehensive gain | — | — | — | — | — | 101 | — | 101 | |
| Net loss | — | — | — | — | — | — | (45,431) | (45,431) | |
| Balance, December 31, 2024 | 61 | $ | - | 66,524 | $7 | $467,087 | $34 | $(384,179) | $82,949 |
(1)
See Note 2.
(2)
Net of expenses of$3.3 million.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.